nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0257	0.0358	CbGbCtD
Etoricoxib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.025	0.0348	CbGbCtD
Etoricoxib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0235	0.0328	CbGbCtD
Etoricoxib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0231	0.0321	CbGbCtD
Etoricoxib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0217	0.0302	CbGbCtD
Etoricoxib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0217	0.0302	CbGbCtD
Etoricoxib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0213	0.0296	CbGbCtD
Etoricoxib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0213	0.0296	CbGbCtD
Etoricoxib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0208	0.029	CbGbCtD
Etoricoxib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0196	0.0273	CbGbCtD
Etoricoxib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0195	0.0272	CbGbCtD
Etoricoxib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0195	0.0272	CbGbCtD
Etoricoxib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.019	0.0265	CbGbCtD
Etoricoxib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0183	0.0256	CbGbCtD
Etoricoxib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0179	0.0249	CbGbCtD
Etoricoxib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0179	0.0249	CbGbCtD
Etoricoxib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0178	0.0248	CbGbCtD
Etoricoxib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0177	0.0246	CbGbCtD
Etoricoxib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0177	0.0246	CbGbCtD
Etoricoxib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0164	0.0229	CbGbCtD
Etoricoxib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0162	0.0225	CbGbCtD
Etoricoxib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0162	0.0225	CbGbCtD
Etoricoxib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0224	CbGbCtD
Etoricoxib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0161	0.0224	CbGbCtD
Etoricoxib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0154	0.0215	CbGbCtD
Etoricoxib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0153	0.0213	CbGbCtD
Etoricoxib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0149	0.0207	CbGbCtD
Etoricoxib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0148	0.0206	CbGbCtD
Etoricoxib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0139	0.0194	CbGbCtD
Etoricoxib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0135	0.0189	CbGbCtD
Etoricoxib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0134	0.0187	CbGbCtD
Etoricoxib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0134	0.0187	CbGbCtD
Etoricoxib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0128	0.0179	CbGbCtD
Etoricoxib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0122	0.0171	CbGbCtD
Etoricoxib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0122	0.0171	CbGbCtD
Etoricoxib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0121	0.0168	CbGbCtD
Etoricoxib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0114	0.0158	CbGbCtD
Etoricoxib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0114	0.0158	CbGbCtD
Etoricoxib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0103	0.0143	CbGbCtD
Etoricoxib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0103	0.0143	CbGbCtD
Etoricoxib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00887	0.0124	CbGbCtD
Etoricoxib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00861	0.012	CbGbCtD
Etoricoxib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00779	0.0109	CbGbCtD
Etoricoxib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00779	0.0109	CbGbCtD
Etoricoxib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00747	0.0104	CbGbCtD
Etoricoxib—MAPK14—blood plasma—acquired immunodeficiency syndrome	0.00368	0.0883	CbGeAlD
Etoricoxib—MAPK14—skin of body—acquired immunodeficiency syndrome	0.00177	0.0425	CbGeAlD
Etoricoxib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00156	0.0375	CbGeAlD
Etoricoxib—Vemurafenib—ALB—acquired immunodeficiency syndrome	0.00148	0.478	CrCbGaD
Etoricoxib—MAPK14—lymphoid tissue—acquired immunodeficiency syndrome	0.00143	0.0344	CbGeAlD
Etoricoxib—MAPK14—digestive system—acquired immunodeficiency syndrome	0.00142	0.034	CbGeAlD
Etoricoxib—MAPK14—blood—acquired immunodeficiency syndrome	0.00135	0.0324	CbGeAlD
Etoricoxib—MAPK14—bone marrow—acquired immunodeficiency syndrome	0.0013	0.0313	CbGeAlD
Etoricoxib—MAPK14—spinal cord—acquired immunodeficiency syndrome	0.0013	0.0312	CbGeAlD
Etoricoxib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00128	0.0307	CbGeAlD
Etoricoxib—MAPK14—vagina—acquired immunodeficiency syndrome	0.00125	0.03	CbGeAlD
Etoricoxib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00121	0.0291	CbGeAlD
Etoricoxib—PTGS2—endothelium—acquired immunodeficiency syndrome	0.00119	0.0286	CbGeAlD
Etoricoxib—MAPK14—lung—acquired immunodeficiency syndrome	0.00118	0.0284	CbGeAlD
Etoricoxib—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.00115	0.0276	CbGeAlD
Etoricoxib—MAPK14—nervous system—acquired immunodeficiency syndrome	0.00109	0.0263	CbGeAlD
Etoricoxib—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.00106	0.0254	CbGeAlD
Etoricoxib—MAPK14—central nervous system—acquired immunodeficiency syndrome	0.00105	0.0253	CbGeAlD
Etoricoxib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000925	0.0222	CbGeAlD
Etoricoxib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00091	0.0218	CbGeAlD
Etoricoxib—Celecoxib—ALB—acquired immunodeficiency syndrome	0.000871	0.281	CrCbGaD
Etoricoxib—MAPK14—brain—acquired immunodeficiency syndrome	0.000837	0.0201	CbGeAlD
Etoricoxib—MAPK14—lymph node—acquired immunodeficiency syndrome	0.000808	0.0194	CbGeAlD
Etoricoxib—Vismodegib—ALB—acquired immunodeficiency syndrome	0.000747	0.241	CrCbGaD
Etoricoxib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000602	0.0144	CbGeAlD
Etoricoxib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000573	0.0138	CbGeAlD
Etoricoxib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000531	0.0127	CbGeAlD
Etoricoxib—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000509	0.0122	CbGeAlD
Etoricoxib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000491	0.0118	CbGeAlD
Etoricoxib—CYP1A2—blood—acquired immunodeficiency syndrome	0.000468	0.0112	CbGeAlD
Etoricoxib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000466	0.0112	CbGeAlD
Etoricoxib—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000447	0.0107	CbGeAlD
Etoricoxib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000444	0.0107	CbGeAlD
Etoricoxib—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000442	0.0106	CbGeAlD
Etoricoxib—CYP2E1—blood—acquired immunodeficiency syndrome	0.000421	0.0101	CbGeAlD
Etoricoxib—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000412	0.00989	CbGeAlD
Etoricoxib—CYP1A2—lung—acquired immunodeficiency syndrome	0.00041	0.00985	CbGeAlD
Etoricoxib—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000407	0.00977	CbGeAlD
Etoricoxib—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.000406	0.00973	CbGeAlD
Etoricoxib—PTGS2—blood—acquired immunodeficiency syndrome	0.000388	0.0093	CbGeAlD
Etoricoxib—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000375	0.009	CbGeAlD
Etoricoxib—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000374	0.00896	CbGeAlD
Etoricoxib—CYP2E1—lung—acquired immunodeficiency syndrome	0.000369	0.00886	CbGeAlD
Etoricoxib—PTGS2—vagina—acquired immunodeficiency syndrome	0.000359	0.00862	CbGeAlD
Etoricoxib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000356	0.00853	CbGeAlD
Etoricoxib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00035	0.0084	CbGeAlD
Etoricoxib—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000342	0.0082	CbGeAlD
Etoricoxib—PTGS2—lung—acquired immunodeficiency syndrome	0.00034	0.00816	CbGeAlD
Etoricoxib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000339	0.00813	CbGeAlD
Etoricoxib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000333	0.008	CbGeAlD
Etoricoxib—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000329	0.0079	CbGeAlD
Etoricoxib—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000315	0.00755	CbGeAlD
Etoricoxib—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000303	0.00727	CbGeAlD
Etoricoxib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000275	0.0066	CbGeAlD
Etoricoxib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000271	0.00649	CbGeAlD
Etoricoxib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000265	0.00635	CbGeAlD
Etoricoxib—CYP2E1—brain—acquired immunodeficiency syndrome	0.000261	0.00627	CbGeAlD
Etoricoxib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000261	0.00625	CbGeAlD
Etoricoxib—PTGS2—brain—acquired immunodeficiency syndrome	0.000241	0.00577	CbGeAlD
Etoricoxib—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000232	0.00558	CbGeAlD
Etoricoxib—CYP2D6—brain—acquired immunodeficiency syndrome	0.000207	0.00496	CbGeAlD
Etoricoxib—MAPK14—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.000166	0.0327	CbGpPWpGaD
Etoricoxib—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.0005	CcSEcCtD
Etoricoxib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000116	0.0005	CcSEcCtD
Etoricoxib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.0005	CcSEcCtD
Etoricoxib—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.0005	CcSEcCtD
Etoricoxib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000116	0.000498	CcSEcCtD
Etoricoxib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000115	0.000496	CcSEcCtD
Etoricoxib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000496	CcSEcCtD
Etoricoxib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000115	0.000496	CcSEcCtD
Etoricoxib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000115	0.000496	CcSEcCtD
Etoricoxib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000494	CcSEcCtD
Etoricoxib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000115	0.000493	CcSEcCtD
Etoricoxib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000115	0.000493	CcSEcCtD
Etoricoxib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000114	0.000492	CcSEcCtD
Etoricoxib—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.000491	CcSEcCtD
Etoricoxib—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000491	CcSEcCtD
Etoricoxib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000114	0.00049	CcSEcCtD
Etoricoxib—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000114	0.00049	CcSEcCtD
Etoricoxib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.000489	CcSEcCtD
Etoricoxib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.000489	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.000113	0.0224	CbGpPWpGaD
Etoricoxib—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000487	CcSEcCtD
Etoricoxib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000486	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.000486	CcSEcCtD
Etoricoxib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000113	0.000485	CcSEcCtD
Etoricoxib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000113	0.000485	CcSEcCtD
Etoricoxib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000113	0.000484	CcSEcCtD
Etoricoxib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000112	0.000484	CcSEcCtD
Etoricoxib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000112	0.000483	CcSEcCtD
Etoricoxib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000482	CcSEcCtD
Etoricoxib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000482	CcSEcCtD
Etoricoxib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000112	0.00048	CcSEcCtD
Etoricoxib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.00048	CcSEcCtD
Etoricoxib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.00048	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000479	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000477	CcSEcCtD
Etoricoxib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000111	0.000476	CcSEcCtD
Etoricoxib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000476	CcSEcCtD
Etoricoxib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.000476	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000476	CcSEcCtD
Etoricoxib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000475	CcSEcCtD
Etoricoxib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000475	CcSEcCtD
Etoricoxib—MAPK14—CD40/CD40L signaling—CD40LG—acquired immunodeficiency syndrome	0.00011	0.0217	CbGpPWpGaD
Etoricoxib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000473	CcSEcCtD
Etoricoxib—Pain—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000473	CcSEcCtD
Etoricoxib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000472	CcSEcCtD
Etoricoxib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00011	0.000472	CcSEcCtD
Etoricoxib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000471	CcSEcCtD
Etoricoxib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Etoricoxib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.00047	CcSEcCtD
Etoricoxib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000109	0.000469	CcSEcCtD
Etoricoxib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000109	0.000468	CcSEcCtD
Etoricoxib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000109	0.000468	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—CCL4—acquired immunodeficiency syndrome	0.000109	0.0214	CbGpPWpGaD
Etoricoxib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000466	CcSEcCtD
Etoricoxib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000465	CcSEcCtD
Etoricoxib—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000464	CcSEcCtD
Etoricoxib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000464	CcSEcCtD
Etoricoxib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000464	CcSEcCtD
Etoricoxib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000462	CcSEcCtD
Etoricoxib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000462	CcSEcCtD
Etoricoxib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000107	0.000461	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000461	CcSEcCtD
Etoricoxib—MAPK14—CD40/CD40L signaling—IL4—acquired immunodeficiency syndrome	0.000107	0.0211	CbGpPWpGaD
Etoricoxib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.00046	CcSEcCtD
Etoricoxib—MAPK14—Cardiac Progenitor Differentiation—CXCR4—acquired immunodeficiency syndrome	0.000106	0.021	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000455	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000455	CcSEcCtD
Etoricoxib—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000454	CcSEcCtD
Etoricoxib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000454	CcSEcCtD
Etoricoxib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000454	CcSEcCtD
Etoricoxib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000454	CcSEcCtD
Etoricoxib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Etoricoxib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000453	CcSEcCtD
Etoricoxib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000452	CcSEcCtD
Etoricoxib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000105	0.000452	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000452	CcSEcCtD
Etoricoxib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000452	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000451	CcSEcCtD
Etoricoxib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000105	0.00045	CcSEcCtD
Etoricoxib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.00045	CcSEcCtD
Etoricoxib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000449	CcSEcCtD
Etoricoxib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000448	CcSEcCtD
Etoricoxib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Etoricoxib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Etoricoxib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Etoricoxib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.000446	CcSEcCtD
Etoricoxib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Etoricoxib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000104	0.000445	CcSEcCtD
Etoricoxib—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000445	CcSEcCtD
Etoricoxib—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000444	CcSEcCtD
Etoricoxib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.000444	CcSEcCtD
Etoricoxib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000442	CcSEcCtD
Etoricoxib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000442	CcSEcCtD
Etoricoxib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000442	CcSEcCtD
Etoricoxib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000441	CcSEcCtD
Etoricoxib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.00044	CcSEcCtD
Etoricoxib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.00044	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000439	CcSEcCtD
Etoricoxib—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000439	CcSEcCtD
Etoricoxib—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Etoricoxib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000437	CcSEcCtD
Etoricoxib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000436	CcSEcCtD
Etoricoxib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000436	CcSEcCtD
Etoricoxib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000435	CcSEcCtD
Etoricoxib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000435	CcSEcCtD
Etoricoxib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000434	CcSEcCtD
Etoricoxib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000433	CcSEcCtD
Etoricoxib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000432	CcSEcCtD
Etoricoxib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.000432	CcSEcCtD
Etoricoxib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000432	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000431	CcSEcCtD
Etoricoxib—Rash—Stavudine—acquired immunodeficiency syndrome	0.0001	0.000431	CcSEcCtD
Etoricoxib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000431	CcSEcCtD
Etoricoxib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.0001	0.000431	CcSEcCtD
Etoricoxib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.00043	CcSEcCtD
Etoricoxib—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.99e-05	0.00043	CcSEcCtD
Etoricoxib—Headache—Stavudine—acquired immunodeficiency syndrome	9.96e-05	0.000428	CcSEcCtD
Etoricoxib—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.96e-05	0.000428	CcSEcCtD
Etoricoxib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	9.94e-05	0.000428	CcSEcCtD
Etoricoxib—Pain—Delavirdine—acquired immunodeficiency syndrome	9.93e-05	0.000427	CcSEcCtD
Etoricoxib—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.93e-05	0.000427	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.93e-05	0.000427	CcSEcCtD
Etoricoxib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.91e-05	0.000426	CcSEcCtD
Etoricoxib—Rash—Abacavir—acquired immunodeficiency syndrome	9.87e-05	0.000425	CcSEcCtD
Etoricoxib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.86e-05	0.000424	CcSEcCtD
Etoricoxib—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.86e-05	0.000424	CcSEcCtD
Etoricoxib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	9.86e-05	0.000424	CcSEcCtD
Etoricoxib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.85e-05	0.000424	CcSEcCtD
Etoricoxib—Headache—Abacavir—acquired immunodeficiency syndrome	9.81e-05	0.000422	CcSEcCtD
Etoricoxib—Infection—Lamivudine—acquired immunodeficiency syndrome	9.8e-05	0.000421	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.79e-05	0.000421	CcSEcCtD
Etoricoxib—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.78e-05	0.000421	CcSEcCtD
Etoricoxib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.77e-05	0.00042	CcSEcCtD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—CCL5—acquired immunodeficiency syndrome	9.75e-05	0.0192	CbGpPWpGaD
Etoricoxib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.72e-05	0.000418	CcSEcCtD
Etoricoxib—Shock—Lamivudine—acquired immunodeficiency syndrome	9.7e-05	0.000417	CcSEcCtD
Etoricoxib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.67e-05	0.000416	CcSEcCtD
Etoricoxib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.66e-05	0.000415	CcSEcCtD
Etoricoxib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.64e-05	0.000415	CcSEcCtD
Etoricoxib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.6e-05	0.000413	CcSEcCtD
Etoricoxib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.58e-05	0.000412	CcSEcCtD
Etoricoxib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.58e-05	0.000412	CcSEcCtD
Etoricoxib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.57e-05	0.000412	CcSEcCtD
Etoricoxib—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.55e-05	0.000411	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.5e-05	0.000408	CcSEcCtD
Etoricoxib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.47e-05	0.000407	CcSEcCtD
Etoricoxib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9.47e-05	0.000407	CcSEcCtD
Etoricoxib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.46e-05	0.000407	CcSEcCtD
Etoricoxib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.45e-05	0.000407	CcSEcCtD
Etoricoxib—Nausea—Stavudine—acquired immunodeficiency syndrome	9.44e-05	0.000406	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.42e-05	0.000405	CcSEcCtD
Etoricoxib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.4e-05	0.000404	CcSEcCtD
Etoricoxib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.35e-05	0.000402	CcSEcCtD
Etoricoxib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.34e-05	0.000402	CcSEcCtD
Etoricoxib—Nausea—Abacavir—acquired immunodeficiency syndrome	9.3e-05	0.0004	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.27e-05	0.000399	CcSEcCtD
Etoricoxib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.26e-05	0.000398	CcSEcCtD
Etoricoxib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.23e-05	0.000397	CcSEcCtD
Etoricoxib—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.22e-05	0.000396	CcSEcCtD
Etoricoxib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.22e-05	0.000396	CcSEcCtD
Etoricoxib—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.19e-05	0.000395	CcSEcCtD
Etoricoxib—Pain—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.000395	CcSEcCtD
Etoricoxib—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.19e-05	0.000395	CcSEcCtD
Etoricoxib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.18e-05	0.000395	CcSEcCtD
Etoricoxib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.14e-05	0.000393	CcSEcCtD
Etoricoxib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.1e-05	0.000391	CcSEcCtD
Etoricoxib—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.09e-05	0.000391	CcSEcCtD
Etoricoxib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.99e-05	0.000386	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000386	CcSEcCtD
Etoricoxib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.94e-05	0.000385	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.000384	CcSEcCtD
Etoricoxib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	8.92e-05	0.000384	CcSEcCtD
Etoricoxib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.91e-05	0.000383	CcSEcCtD
Etoricoxib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.85e-05	0.000381	CcSEcCtD
Etoricoxib—Pain—Saquinavir—acquired immunodeficiency syndrome	8.84e-05	0.00038	CcSEcCtD
Etoricoxib—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.84e-05	0.00038	CcSEcCtD
Etoricoxib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.79e-05	0.000378	CcSEcCtD
Etoricoxib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.79e-05	0.000378	CcSEcCtD
Etoricoxib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.78e-05	0.000378	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.78e-05	0.000378	CcSEcCtD
Etoricoxib—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.77e-05	0.000377	CcSEcCtD
Etoricoxib—Rash—Zidovudine—acquired immunodeficiency syndrome	8.71e-05	0.000375	CcSEcCtD
Etoricoxib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.71e-05	0.000375	CcSEcCtD
Etoricoxib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.7e-05	0.000374	CcSEcCtD
Etoricoxib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.68e-05	0.000373	CcSEcCtD
Etoricoxib—Headache—Zidovudine—acquired immunodeficiency syndrome	8.66e-05	0.000372	CcSEcCtD
Etoricoxib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.59e-05	0.000369	CcSEcCtD
Etoricoxib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.57e-05	0.000369	CcSEcCtD
Etoricoxib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.56e-05	0.000368	CcSEcCtD
Etoricoxib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.53e-05	0.000367	CcSEcCtD
Etoricoxib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.52e-05	0.000366	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.51e-05	0.000366	CcSEcCtD
Etoricoxib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.5e-05	0.000366	CcSEcCtD
Etoricoxib—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.5e-05	0.000365	CcSEcCtD
Etoricoxib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.49e-05	0.000365	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CCL4—acquired immunodeficiency syndrome	8.47e-05	0.0167	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.45e-05	0.000364	CcSEcCtD
Etoricoxib—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.43e-05	0.000363	CcSEcCtD
Etoricoxib—Pain—Lamivudine—acquired immunodeficiency syndrome	8.43e-05	0.000363	CcSEcCtD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	8.35e-05	0.0165	CbGpPWpGaD
Etoricoxib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.33e-05	0.000358	CcSEcCtD
Etoricoxib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.31e-05	0.000357	CcSEcCtD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	8.25e-05	0.0163	CbGpPWpGaD
Etoricoxib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.22e-05	0.000353	CcSEcCtD
Etoricoxib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.21e-05	0.000353	CcSEcCtD
Etoricoxib—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.21e-05	0.000353	CcSEcCtD
Etoricoxib—MAPK14—BCR signaling pathway—CD79A—acquired immunodeficiency syndrome	8.2e-05	0.0162	CbGpPWpGaD
Etoricoxib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.17e-05	0.000351	CcSEcCtD
Etoricoxib—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.17e-05	0.000351	CcSEcCtD
Etoricoxib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	8.13e-05	0.00035	CcSEcCtD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	8.12e-05	0.016	CbGpPWpGaD
Etoricoxib—Rash—Indinavir—acquired immunodeficiency syndrome	8.1e-05	0.000348	CcSEcCtD
Etoricoxib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.09e-05	0.000348	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.06e-05	0.000347	CcSEcCtD
Etoricoxib—Headache—Indinavir—acquired immunodeficiency syndrome	8.05e-05	0.000346	CcSEcCtD
Etoricoxib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.03e-05	0.000345	CcSEcCtD
Etoricoxib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.95e-05	0.000342	CcSEcCtD
Etoricoxib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.91e-05	0.00034	CcSEcCtD
Etoricoxib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000337	CcSEcCtD
Etoricoxib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.8e-05	0.000335	CcSEcCtD
Etoricoxib—MAPK14—IL-4 Signaling Pathway—IL4—acquired immunodeficiency syndrome	7.73e-05	0.0152	CbGpPWpGaD
Etoricoxib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.72e-05	0.000332	CcSEcCtD
Etoricoxib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.71e-05	0.000331	CcSEcCtD
Etoricoxib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.68e-05	0.00033	CcSEcCtD
Etoricoxib—Rash—Efavirenz—acquired immunodeficiency syndrome	7.65e-05	0.000329	CcSEcCtD
Etoricoxib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.65e-05	0.000329	CcSEcCtD
Etoricoxib—Nausea—Indinavir—acquired immunodeficiency syndrome	7.63e-05	0.000328	CcSEcCtD
Etoricoxib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.62e-05	0.000328	CcSEcCtD
Etoricoxib—Headache—Efavirenz—acquired immunodeficiency syndrome	7.61e-05	0.000327	CcSEcCtD
Etoricoxib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.6e-05	0.000327	CcSEcCtD
Etoricoxib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.42e-05	0.000319	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—CCL3—acquired immunodeficiency syndrome	7.41e-05	0.0146	CbGpPWpGaD
Etoricoxib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.39e-05	0.000318	CcSEcCtD
Etoricoxib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.35e-05	0.000316	CcSEcCtD
Etoricoxib—Rash—Delavirdine—acquired immunodeficiency syndrome	7.32e-05	0.000315	CcSEcCtD
Etoricoxib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.32e-05	0.000315	CcSEcCtD
Etoricoxib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.31e-05	0.000315	CcSEcCtD
Etoricoxib—Headache—Delavirdine—acquired immunodeficiency syndrome	7.28e-05	0.000313	CcSEcCtD
Etoricoxib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.27e-05	0.000312	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—CCL3—acquired immunodeficiency syndrome	7.24e-05	0.0143	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	7.22e-05	0.0142	CbGpPWpGaD
Etoricoxib—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.21e-05	0.00031	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	7.11e-05	0.014	CbGpPWpGaD
Etoricoxib—MAPK14—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	7.11e-05	0.014	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	7.1e-05	0.014	CbGpPWpGaD
Etoricoxib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.1e-05	0.000305	CcSEcCtD
Etoricoxib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.08e-05	0.000304	CcSEcCtD
Etoricoxib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.07e-05	0.000304	CcSEcCtD
Etoricoxib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.98e-05	0.0003	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	6.92e-05	0.0137	CbGpPWpGaD
Etoricoxib—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.9e-05	0.000297	CcSEcCtD
Etoricoxib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.84e-05	0.000294	CcSEcCtD
Etoricoxib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.83e-05	0.000294	CcSEcCtD
Etoricoxib—Rash—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.000291	CcSEcCtD
Etoricoxib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.77e-05	0.000291	CcSEcCtD
Etoricoxib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.75e-05	0.00029	CcSEcCtD
Etoricoxib—Headache—Ritonavir—acquired immunodeficiency syndrome	6.73e-05	0.000289	CcSEcCtD
Etoricoxib—MAPK14—Regulation of retinoblastoma protein—CSF2—acquired immunodeficiency syndrome	6.69e-05	0.0132	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—MBL2—acquired immunodeficiency syndrome	6.68e-05	0.0132	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—CCR5—acquired immunodeficiency syndrome	6.61e-05	0.013	CbGpPWpGaD
Etoricoxib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.57e-05	0.000283	CcSEcCtD
Etoricoxib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.52e-05	0.00028	CcSEcCtD
Etoricoxib—Rash—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.00028	CcSEcCtD
Etoricoxib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.51e-05	0.00028	CcSEcCtD
Etoricoxib—Headache—Saquinavir—acquired immunodeficiency syndrome	6.48e-05	0.000279	CcSEcCtD
Etoricoxib—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.38e-05	0.000274	CcSEcCtD
Etoricoxib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.27e-05	0.00027	CcSEcCtD
Etoricoxib—Rash—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000267	CcSEcCtD
Etoricoxib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.21e-05	0.000267	CcSEcCtD
Etoricoxib—Headache—Lamivudine—acquired immunodeficiency syndrome	6.18e-05	0.000266	CcSEcCtD
Etoricoxib—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.14e-05	0.000264	CcSEcCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—CD79A—acquired immunodeficiency syndrome	6.1e-05	0.012	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IFNA1—acquired immunodeficiency syndrome	6.04e-05	0.0119	CbGpPWpGaD
Etoricoxib—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000252	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CCL3—acquired immunodeficiency syndrome	5.79e-05	0.0114	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—CSF2—acquired immunodeficiency syndrome	5.62e-05	0.0111	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL4—acquired immunodeficiency syndrome	5.53e-05	0.0109	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—acquired immunodeficiency syndrome	5.4e-05	0.0106	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—acquired immunodeficiency syndrome	5.34e-05	0.0105	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—acquired immunodeficiency syndrome	5.25e-05	0.0104	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	5.22e-05	0.0103	CbGpPWpGaD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	4.91e-05	0.00968	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—CCL5—acquired immunodeficiency syndrome	4.8e-05	0.00946	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	4.78e-05	0.00942	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IFNA1—acquired immunodeficiency syndrome	4.71e-05	0.0093	CbGpPWpGaD
Etoricoxib—MAPK14—IL2-mediated signaling events—IFNG—acquired immunodeficiency syndrome	4.67e-05	0.00922	CbGpPWpGaD
Etoricoxib—MAPK14—Monoamine Transport—TNF—acquired immunodeficiency syndrome	4.6e-05	0.00907	CbGpPWpGaD
Etoricoxib—PTGS2—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	4.46e-05	0.00879	CbGpPWpGaD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	4.36e-05	0.0086	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IFNG—acquired immunodeficiency syndrome	4.35e-05	0.00859	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	4.29e-05	0.00847	CbGpPWpGaD
Etoricoxib—MAPK14—IL2-mediated signaling events—IL2—acquired immunodeficiency syndrome	4.15e-05	0.00819	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	4.15e-05	0.00818	CbGpPWpGaD
Etoricoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—acquired immunodeficiency syndrome	4.01e-05	0.0079	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	3.82e-05	0.00753	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	3.81e-05	0.00752	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CCL5—acquired immunodeficiency syndrome	3.74e-05	0.00738	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—TNF—acquired immunodeficiency syndrome	3.7e-05	0.00729	CbGpPWpGaD
Etoricoxib—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	3.6e-05	0.00709	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—IL6—acquired immunodeficiency syndrome	3.53e-05	0.00697	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IFNG—acquired immunodeficiency syndrome	3.35e-05	0.0066	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	3.22e-05	0.00634	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	3.17e-05	0.00626	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	3e-05	0.00591	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	2.98e-05	0.00589	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	2.98e-05	0.00588	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL2—acquired immunodeficiency syndrome	2.97e-05	0.00586	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	2.95e-05	0.00581	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	2.87e-05	0.00567	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	2.82e-05	0.00556	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	2.74e-05	0.00541	CbGpPWpGaD
Etoricoxib—MAPK14—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	2.73e-05	0.00538	CbGpPWpGaD
Etoricoxib—MAPK14—IL6-mediated signaling events—IL6—acquired immunodeficiency syndrome	2.73e-05	0.00538	CbGpPWpGaD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	2.71e-05	0.00535	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	2.64e-05	0.00521	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	2.6e-05	0.00513	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.54e-05	0.00502	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.42e-05	0.00478	CbGpPWpGaD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	2.37e-05	0.00468	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	2.27e-05	0.00448	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	2.21e-05	0.00437	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.2e-05	0.00433	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—MBL2—acquired immunodeficiency syndrome	2.14e-05	0.00422	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	2.12e-05	0.00419	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	2.05e-05	0.00405	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	2.02e-05	0.00399	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.02e-05	0.00398	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	1.92e-05	0.00379	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	1.88e-05	0.0037	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.86e-05	0.00368	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.82e-05	0.00359	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.76e-05	0.00347	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	1.75e-05	0.00345	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—CCNT1—acquired immunodeficiency syndrome	1.74e-05	0.00343	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	1.71e-05	0.00337	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	1.7e-05	0.00335	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	1.68e-05	0.00332	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.68e-05	0.00331	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CCR2—acquired immunodeficiency syndrome	1.68e-05	0.00331	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.66e-05	0.00327	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	1.65e-05	0.00326	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.62e-05	0.0032	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.61e-05	0.00317	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	1.6e-05	0.00315	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	1.59e-05	0.00314	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	1.57e-05	0.00309	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ACTG1—acquired immunodeficiency syndrome	1.51e-05	0.00299	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	1.51e-05	0.00298	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	1.5e-05	0.00296	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.47e-05	0.00289	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	1.43e-05	0.00283	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	1.42e-05	0.0028	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	1.42e-05	0.0028	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	1.41e-05	0.00279	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.37e-05	0.00271	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	1.35e-05	0.00267	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.34e-05	0.00265	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	1.33e-05	0.00263	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.31e-05	0.00259	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.31e-05	0.00258	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	1.27e-05	0.00251	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	1.27e-05	0.0025	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MBL2—acquired immunodeficiency syndrome	1.25e-05	0.00246	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.24e-05	0.00245	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.24e-05	0.00245	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.22e-05	0.00241	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	1.21e-05	0.00239	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	1.2e-05	0.00236	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	1.15e-05	0.00226	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.14e-05	0.00224	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	1.13e-05	0.00223	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.13e-05	0.00223	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.13e-05	0.00223	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.1e-05	0.00217	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.08e-05	0.00213	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.05e-05	0.00208	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	1.03e-05	0.00204	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	1.03e-05	0.00203	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.02e-05	0.00202	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.02e-05	0.002	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CCR2—acquired immunodeficiency syndrome	9.76e-06	0.00193	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	9.22e-06	0.00182	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—IL6—acquired immunodeficiency syndrome	9.07e-06	0.00179	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IFNA1—acquired immunodeficiency syndrome	8.79e-06	0.00173	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ALB—acquired immunodeficiency syndrome	8.55e-06	0.00169	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD79A—acquired immunodeficiency syndrome	8.53e-06	0.00168	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	8.48e-06	0.00167	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	8.41e-06	0.00166	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	8.36e-06	0.00165	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	8.34e-06	0.00165	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	7.84e-06	0.00155	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	7.21e-06	0.00142	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	7.19e-06	0.00142	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	7.15e-06	0.00141	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.03e-06	0.00139	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.98e-06	0.00138	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD40LG—acquired immunodeficiency syndrome	6.96e-06	0.00137	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—IL2—acquired immunodeficiency syndrome	6.93e-06	0.00137	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD8A—acquired immunodeficiency syndrome	6.88e-06	0.00136	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CSF2—acquired immunodeficiency syndrome	6.88e-06	0.00136	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	6.86e-06	0.00135	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CD4—acquired immunodeficiency syndrome	6.78e-06	0.00134	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-B—acquired immunodeficiency syndrome	6.62e-06	0.00131	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.43e-06	0.00127	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.31e-06	0.00124	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	6.11e-06	0.00121	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.93e-06	0.00117	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.93e-06	0.00117	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	5.55e-06	0.00109	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	5.41e-06	0.00107	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.15e-06	0.00102	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.97e-06	0.000981	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	4.72e-06	0.00093	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.51e-06	0.00089	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.45e-06	0.000877	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.15e-06	0.000819	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IFNG—acquired immunodeficiency syndrome	4.09e-06	0.000807	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.07e-06	0.000802	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD4—acquired immunodeficiency syndrome	3.95e-06	0.000779	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	3.71e-06	0.000732	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.67e-06	0.000724	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL2—acquired immunodeficiency syndrome	3.63e-06	0.000717	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.61e-06	0.000712	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.29e-06	0.000649	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.81e-06	0.000555	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.35e-06	0.000464	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	2.33e-06	0.00046	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	2.21e-06	0.000437	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—acquired immunodeficiency syndrome	2.14e-06	0.000421	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	2.08e-06	0.000411	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.61e-06	0.000317	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.48e-06	0.000292	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.47e-06	0.000289	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.38e-06	0.000272	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	1.26e-06	0.000249	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.25e-06	0.000247	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	9.67e-07	0.000191	CbGpPWpGaD
